Periostin can predict pulmonary sequelae after COVID-19

this periostina key protein in wound healing, may be Biomarkers Prognostic Appearance pulmonary fibrosis After covid-19.This was revealed by a multicenter study by INCLIVA Institute of Healthof Valencia Clinical Hospitaland published in American Journal of Respiratory Cell and Molecular Biology.

after illness Coronavirus diseasethis sequelae of pulmonary fibrosis They can be very wide. In addition, there are serious concerns about the long-term impact of the SARS-CoV-2 pandemic.There have been many related incidents Biomarkers implicated in the pathogenesis of fibrosis in interstitial lung diseases, especially idiopathic pulmonary fibrosis (idiopathic pulmonary fibrosis).

this idiopathic pulmonary fibrosis (idiopathic pulmonary fibrosis) is a rare chronic interstitial disease fibrosiswhich results in a loss of lung function irreversible. The disease is pathologically characterized by a poor prognosis, with untreated five-year survival rates ranging from 20% to 40%.exist Spain

number of patients idiopathic pulmonary fibrosis The number of cases ranged from 8,000 to 12,000, with an incidence rate of 4.6-7.4 cases per 100,000 residents, a female prevalence rate of 13 cases/100,000 residents, and a male prevalence rate of 20 cases/100,000 residents.

The researchers found that periostin measured 2 months after admission predicted the presence of radiographic fiber changes and impaired diffusion at 12 months.

Against this background, the purpose of this study was to analyze the presence of certain factors Biomarkers of Fibrogenesis pneumonia patient Coronavirus diseaseit can predict pulmonary sequelae after Coronavirus disease. Therefore, the researchers found that periostin Measurements taken two months after admission predict the presence of Radiological fiber changes The spread worsened at twelve months after admission.

this periostin It is an essential protein for wound healing.Because it mediates tissue remodeling, elevated levels are detected in patients with idiopathic pulmonary fibrosiswith the following regions active fibrosis in the lungs.

This study was conducted on patients admitted to the hospital with: bilateral pneumonia go through Coronavirus disease. Patients were divided into two groups according to severity, and blood samples, respiratory function tests, and high-resolution CT scans were performed 2 and 12 months after discharge. A total of 135 patients were evaluated at 12 months, with a mean age of 61 years.

There were differences between the groups with respect to age, radiographic involvement, length of hospital stay, and laboratory parameters of inflammation. Differences between two and twelve months were also found in all functional tests.

At 12 months, 63% of patients were fully resolved on high-resolution computed tomography, but fibrous change Continued at 29.4%.Analysis Biomarkers show difference at two months periostin, but no difference was found at twelve months.The results show periostin Presence can be predicted early after discharge Fibrotic changes in the lungs.

Protein may be good prognostic biomarker of fibrotic changes in lung after Covid-19, study suggests

The study provides new knowledge for personalized follow-up of these patients, as it shows that the protein could be a good treatment. Biomarkers Prognosis after changes in pulmonary fibrosis Coronavirus disease.This will allow selection of those at high risk of developing progressive fibrosis.

The new findings have been acknowledged in an editorial in the publication titled ‘A pandemic within a pandemic; predicting post-COVID-19’ pulmonary fibrosis. This highlights the search for “Biomarkers Proven to Guide Personalized Healthcare Decisions Pulmonary Fibrosis post-Covid-19″ and the relevance of the results obtained.

However, the researchers consider conducting new studies with larger population samples and considering other types of patients.This is because the population studied was relatively sick and all were hospitalized, so it is unclear whether periostin will be valuable Biomarkers present in patients Pulmonary Fibrosis But no hospitalization is required.